

For Release Feb. 5, 2007

Contacts: Kimberly Snyder
 Respironics, Inc.
 US Marketing Manager
 Home Respiratory
 724-387-7745

 Michael Barsevich
 Respironics, Inc.
 Marketing Communications
 724-387-5267

New EverFlo™ Stationary Oxygen Concentrator Designed to Reduce Homecare Provider Operating Costs; Weighs 31 Pounds

Murrysville, Pa., Feb. 5, 2007 – Respironics, Inc. (NASDAQ/NMS Symbol: RESP) announced today the launch of EverFlo, its five-liter, stationary oxygen concentrator and newest member of the Company's Freedom Series™ of oxygen therapy products. The 31-pound concentrator is designed to provide oxygen therapy to prescribed patients while reducing the costs associated with the delivery of therapy such as maintenance, unscheduled patient calls and visits, and shipping and storage. These nonequipment-related expenses account for 72 percent of the costs of providing home oxygen therapy to Medicare beneficiaries, according to a 2006 Morrison Informatics study published by the American Association for Homecare.



EverFlo weighs 31 pounds and stands 23 inches high.

Specific provider cost-saving features include an internal filter that needs to be changed only once every two years. Additionally, the EverFlo's light weight (31 pounds) and small size make it easier and less expensive for homecare providers to transport and store.

For the patient's convenience and comfort, the lighter weight EverFlo concentrator uses less power and produces less heat and noise. And with EverFlo, patients are not required to replace a filter.

“The new EverFlo represents an evolution in five-liter oxygen concentrators

CORPORATE SERVICES

1010 Murry Ridge Lane • Murrysville, PA 15668
Phone 724.387.5200 • Fax 724.387.5010

because it is significantly lighter, smaller and easier to use and maintain and offers feature enhancements that are specifically designed to further help reduce operating costs for the homecare business owner,” said John Frank, vice president and general manager of Respironics’ Home Respiratory business. “That translates into a better solution for homecare providers and patients,” added Mr. Frank.

The five-liter EverFlo stationary oxygen concentrator is currently available in the United States and Canada and can be purchased with or without an oxygen percentage indicator. The Company intends to release EverFlo in Africa, Asia, Australia, Europe and the Middle East in the near future. For more information, go to everflo.respironics.com.

About the Freedom Series

EverFlo is part of the Freedom Series™ of oxygen therapy products from Respironics designed to deliver clinically superior treatment and more freedom – freedom from worry, freedom from deliveries, freedom from complicated maintenance. Most importantly, the Freedom Series frees patients and providers of some of the more demanding aspects of oxygen therapy.

About Respironics

Respironics’ Sleep and Home Respiratory Group is recognized worldwide for its continuous stream of medical innovations and advancements in the management of sleep disorders and chronic respiratory problems. The Group integrates state-of-the-art technology in diagnostics, therapy and monitoring with strategic solutions to help health care providers and sleep centers care for patients efficiently and cost-effectively.

Respironics is a leading developer, manufacturer, and distributor of innovative products and programs that serve the global sleep and respiratory markets. Focusing on emerging market needs, the Company is committed to providing valued solutions to help improve outcomes for patients, clinicians and health care providers. Respironics markets its products in 131 countries and employs more than 4,800



associates worldwide. Further information can be found on the Company's Web site: www.respironics.com.

###

This document contains forward-looking statements, including statements relating to, among other things, developments in the health care industry; the success of the Company's marketing, sales, and promotion programs; future sales, acceptance, and quality of the Company's products and programs; the timing and success of new product introductions; new product development; anticipated cost savings; FDA and other regulatory requirements, enforcement actions, product recalls or related field actions; future results from acquisitions and strategic investments; growth rates in foreign markets; regulations and other factors affecting operations and sales outside the United States; foreign currency fluctuations; the effects of a major earthquake, cyber-attack or other catastrophic event that results in the destruction or disruption of any critical business or information technology systems; customer consolidation and concentration; increasing price competition and other competitive factors in the manufacture, distribution, and sale of products; interest rate fluctuations; expiration of intellectual property rights; intellectual property and related litigation; other litigation; future levels of earnings and revenues; the number of equity awards granted to employees and changes in the Company's stock price; and third party reimbursement; all of which are subject to change. Actual results may differ materially from those described in any forward-looking statements. Additional information on potential factors that could affect the Company's financial results are included in the reports filed with the SEC, including the reports on Form 10-K, 10-Q and 8-K. The Company will not change its financial outlook or guidance based on this announcement.

© 2007 Respironics, Inc. and its affiliates

CORPORATE SERVICES
1010 Murry Ridge Lane • Murrysville, PA 15668
Phone 724.387.5200 • Fax 724.387.5010